JUPITER, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company announced it has signed a fully funded evaluation agreement including commercial option with an undisclosed leading global biopharmaceutical company to design and produce recombinant proteins using Dyadic's C1 filamentous fungal based microbial protein production platform. Under the agreement, research and development activities will be funded by the collaborator.
“Dyadic's C1 protein expression platform is gaining increased traction in research and development targeting infectious and other diseases,” said CEO Mark Emalfarb, "We are glad to see the progress of our C1-cell protein production platform for human and animal biopharmaceuticals and we believe the recent positive Phase I first in human data for a recombinant vaccine produced using C1 will spark further interest in the adoption of Dyadic’s C1 technology.”
Dyadic is committed to enabling its partners and collaborators in the development of effective preventative and therapeutic treatments globally. Dyadic is increasing global outreach to fulfill its mission to make a difference in global health by building an active pipeline through advancing its proprietary microbial platform technologies to create needed products such as recombinant human and bovine albumin and other biologic vaccines, antibodies, and products.
https://www.globenewswire.com/news-release/2024/02/06/2824325/0/en/Dyadic-Announces-Research-and-Development-Collaboration-Agreement-with-Global-Biopharmaceutical-Company.html